A similar study found that in 500 non–small cell lung cancer (NSCLC) patients, PD-L1 expression on CD68+ macrophages was associated with increased CD8+ T cell infiltration and better response to anti-PD-1/PD-L1 therapy [23]. This evidence concerns the gene CD8A and non-small cell lung carcinoma.